Skip to main content

IRWD

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

IRWD Price
Price Chart

Forward-looking statistics

Beta
2.35
Risk
88.74%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees400
Market cap$1.0B

Fundamentals

Enterprise value$606.7M
Revenue$317.7M
Revenue per employee
Profit margin-10.18%
Debt to equity-1.79

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.19
Dividend per share
Revenue per share$1.99
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+1.3
Credit+1.2
Liquidity+0.8
Inflation+0.1
Commodities-0.2
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio2.02
Price to sales0.39
P/E Ratio2.02
Enterprise Value to Revenue1.91
Price to book-0.37

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 6, 2025)
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Ironwood Pharmaceuticals, Inc.  IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.

Benzinga (April 14, 2025)
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors.

CNBC (January 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free